In 2022, the Global Central Lab Industry was valued at $2,422.7 million. The central lab sector is expected to grow at a high CAGR of 5.8% between 2023 and 2033. This optimistic trend shows a potential market value increase of $4,473.5 million by 2033, greatly exceeding the $2,543.9 million threshold in 2023.
The importance of central labs in accelerating pharmaceutical development cannot be emphasized. These labs let pharmaceutical companies launch new chemicals to the market more quickly by removing needless steps. Furthermore, central labs play a critical role in genetic testing services for a wide range of illnesses, including sickle cell anemia, Alzheimer’s, and Parkinson’s.
The evolution of the central lab industry is expected to receive a substantial boost over the projected period due to the increasing number of clinical trials. The prevalence of genetic illnesses has set a significant trend, leading to a surge in demand for private layers involved in the central lab sector.
Request a Sample of this Report Now!
https://www.futuremarketinsights.com/reports/sample/rep-gb-9067
In recent years, pharmaceutical and biopharmaceutical firms have entirely outsourced their research and development activities to central labs operated by private players. Besides lowering expenses for pharmaceutical and biotechnology businesses, central labs guarantee that findings are supplied more quickly and accurately.
Key Takeaways from the Global Central Lab Industry Study Report by FMI
- The United States is the leading region, with almost 51% share of the total demand for central lab services generated worldwide in 2022.
- Germany is the leading country in Europe that garnered almost 25% share of the total demand for central lab services in Europe in 2022.
- The demand for central labs in the United Kingdom is poised to register a higher CAGR of 5.1% in Europe from 2023 to 2033.
- China is the leading market in Asia, with a projected CAGR of 7.6% for its clinical central laboratory market from 2023 to 2033.
- India is likely to follow China in demand for clinical trials with an annual growth rate of 6% during the forecast years.
“Central labs are increasingly adopting cutting-edge technical solutions, which is helping the overall market to expand and is projected to continue. Correspondingly, the majority of central laboratories have fully automated their procedures, allowing them to save money and time,” opines Sabyasachi Ghosh, Associate Vice President at Future Market Insights (FMI).
Competitive Landscape for the Global Central Lab Industry Players
The overall market is fairly consolidated, as only some players successfully create a value chain by creating central labs at different locations. However, escalating government support in emerging economies following the pandemic is expected to encourage many new players to enter the market, intensifying competition.
Global Central Lab Industry Key Companies Profiled
- Covance (Labcorp)
- Eurofins Global Central Library
- PPD Central Lab
- ICON Central Labs
- Medpace Reference Laboratory
- Q² Solutions
- ACM Global Laboratories
- Labconnect Inc.
- Cerba Research
- Medicover Integrated Clinical Services
- Versiti Inc.
- A.P. Møller Holding A/S
- Ampersand Capital Partners
- Lambda Therapeutics Research Ltd
- Cirion Biopharma Research Inc.
Recent Developments by the Global Central Lab Service Providers
- LabConnect Incorporate announced the expansion of its facilities in Johnson City in September 2020 to increase the production of clinical trial kits. This expansion has been planned to support the company’s rapid growth in the fields of immuno-oncology research and cell and gene therapy. The corporation is also expanding the storage capacity of its biorepository for specimens by moving its headquarters to Tennessee.
- Labcorp or Covance Inc., a preeminent global life sciences company, declared that it was expanding its CB trial laboratory in June 2022. Its central laboratory is shared by a top Japanese provider of clinical laboratory testing services named BML. The company decided to expand existing laboratory capabilities in Japan to strengthen its central laboratory presence and drug development.
Click Here To Buy Full Report! https://www.futuremarketinsights.com/checkout/9067
Key Segments Profiled in the Global Central Lab Industry Survey
By Service Type:
- Genetic Services
- Biomarker Services
- Microbiology Services
- Special Chemistry Services
- Other Service Types
By End User:
- Pharmaceutical Companies
- Biotechnology Companies
- Academic and Research Institutes
By Region:
- North America
- Latin America
- Western Europe
- Eastern Europe
- Asia Pacific Excluding Japan
- Japan
- The Middle East & Africa (MEA)
Author
Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.
Identifying key challenges faced by clients and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.
Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI is the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube
